Laparoscopic hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) in the management of refractory malignant ascites: A multi-institutional retrospective analysis in 52 patients

M. Valle, K. Van Der Speeten, A. Garofalo

Research output: Contribution to journalArticlepeer-review

Abstract

Malignant ascites is a debilitating condition affecting cancer patients in their terminal stage of disease. Recently, laparoscopic hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) was introduced as a new approach. From September 2001 to August 2008, 52 patients were treated with this new modality. No treatment-related mortality was observed. Median survival was 98 days. One patient developed a clinical recurrence. Laparoscopic HIPEC is a safe and effective method for palliating malignant ascites.

Original languageEnglish
Pages (from-to)331-334
Number of pages4
JournalJournal of Surgical Oncology
Volume100
Issue number4
DOIs
Publication statusPublished - Sep 15 2009

Keywords

  • Chemotherapy
  • Intraperitoneal
  • Laparoscopy
  • Malignant ascites

ASJC Scopus subject areas

  • Surgery
  • Oncology

Fingerprint

Dive into the research topics of 'Laparoscopic hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) in the management of refractory malignant ascites: A multi-institutional retrospective analysis in 52 patients'. Together they form a unique fingerprint.

Cite this